Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYCV7U)

Drug Name

N,O6-Disulfo-Glucosamine Drug Info

Synonyms

N,O6-Disulfo-Glucosamine; 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose; SGN; AC1L9G8A; SCHEMBL1009127; DB03959; 6-O-sulfo-N-sulfo-alpha-d-glucosamine; J3.578.180C; 6-O-Sulfo-2-(sulfoamino)-2-deoxy-alpha-D-glucopyranose; [(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid; WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O]/1/

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 444389
TTD Drug ID: DMYCV7U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Heparin-binding growth factor 1 (FGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CVBT-141H	DMYPXQ2	Coronary artery disease	BA80	Phase 2	[2]
Riferminogene pecaplasmid	DMBKN4P	Critical limb ischemia	BD4Y	Discontinued in Phase 3	[3]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
O2-Sulfo-Glucuronic Acid	DME78MS	Discovery agent	N.A.	Investigative	[1]
Naphthalene Trisulfonate	DML6FI3	Discovery agent	N.A.	Investigative	[1]
5-AMINO-NAPHTALENE-2-MONOSULFONATE	DMYTUNE	Discovery agent	N.A.	Investigative	[4]
Sucrose Octasulfate	DMET64R	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Drug(s) Targeting Fibroblast growth factor-2 (FGF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sucralfate	DMP9HBO	Acne vulgaris	ED80	Approved	[5]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
DVC1-0101	DMUGBQK	Arteriosclerosis	BD40	Phase 2	[7]
Bemarituzumab	DMWNYIE	Gastric adenocarcinoma	2B72	Phase 2	[8]
FPA144	DM1EBRK	Bladder cancer	2C94	Phase 1	[9]
TGP-580	DMYN6G0	Neurodegenerative disorder	8A20-8A23	Discontinued in Phase 2	[10]
RG-8803	DMI0CYV	Diabetic retinopathy	9B71.0	Terminated	[11]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[1]
BIBF100	DMUWO6D	Multiple myeloma	2A83	Investigative	[12]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid	DM9KUQZ	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VM-202	DMSW80U	Angina pectoris	BA40	Phase 3	[13]
Donaperminogene seltoplasmid	DMH8IT5	Diabetic foot ulcer	BD54	Phase 3	[14]
ANG-3777	DMGP8WX	Delayed graft function	4B24.0	Phase 3	[15]
Ficlatuzumab	DMG65WH	Multiple myeloma	2A83	Phase 2	[8]
Collategene	DM27H0P	Peripheral Ischemic Ulcers	BD41	Phase 2	[16]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[8]
ABI-011	DM1KD7U	Lymphoma	2A80-2A86	Phase 1	[8]
TAK-701	DML3M0O	Advanced malignancy	2A00-2F9Z	Phase 1	[17]
Rilotumumab	DMD8ZSW	Grade IV malignant glioma	2A00.0	Discontinued in Phase 2	[18]
O2-Sulfo-Glucuronic Acid	DME78MS	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-2 (FGF2)	TTGKIED	FGF2_HUMAN	Inhibitor	[1]
Heparin-binding growth factor 1 (FGF1)	TTMY81X	FGF1_HUMAN	Inhibitor	[1]
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	Clinical pipeline report, company report or official report of CVBT.
3	Riferminogene pecaplasmide. Am J Cardiovasc Drugs. 2010;10(5):343-6.
4	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
5	Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
6	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
7	DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
11	US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
12	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
13	Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
14	Clinical pipeline report, company report or official report of ViroMed.
15	Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
16	Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
17	Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
18	Clinical pipeline report, company report or official report of Amgen (2009).